UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 3, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At August 8, 2016, 6,065,652,424 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 3, 2016 and June 28, 2015

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 3, 2016 and June 28, 2015

Condensed Consolidated Balance Sheets as of July 3, 2016 and December 31, 2015

Condensed Consolidated Statements of Cash Flows for the six months ended July 3, 2016 and June 28, 2015

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

47

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

48

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

101

Item 4.

Controls and Procedures

101

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

102

Item 1A.

Risk Factors

102

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

103

Item 3.

Defaults Upon Senior Securities

103

Item 4.

Mine Safety Disclosures

103

Item 5.

Other Information

103

Item 6.

Exhibits

104

Signature

105

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2015 Financial Report

Financial Report for the fiscal year ended December 31, 2015, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2015

2015 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2015

ACA

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Allergan

Allergan plc

Alliance revenues

revenues from alliance agreements under which we co-promote products discovered by other companies

AM-Pharma

AM-Pharma B.V.

Anacor

Anacor Pharmaceuticals, Inc.

ASU

Accounting Standards Update

Baxter

Baxter International Inc.

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, Scandinavia, South Korea, Finland and New Zealand

DOJ

U.S. Department of Justice

DVT

deep vein thrombosis

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey

EPA

U.S. Environmental Protection Agency

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GHD

growth hormone deficiency

GIST

gastrointestinal stromal tumors

GEP

Global Established Pharmaceutical segment

GIP

Global Innovative Pharmaceutical segment

GPD

Global Product Development organization

GS&Co.

Goldman, Sachs & Co.

HER2-

human epidermal growth factor receptor 2-negative

hGH-CTP

human growth hormone

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

IH

Innovative Health

IPR&D

in-process research and development

IRC

Internal Revenue Code

IRS

U.S. Internal Revenue Service

LDL

low density lipoprotein

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCO

managed care organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

MDV

multi-dose vial

Moody s

Moody s Investors Service

mRCC

metastatic renal cell carcinoma

NDA

new drug application

NOAC

Novel Oral Anticoagulant

NovaQuest

NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PBM

Pharmacy Benefit Manager

PDUFA

Prescription Drug User Fee Act

PE

pulmonary embolism

PGS

Pfizer Global Supply

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2016

RAR

Revenue Agent s Report

RCC

renal cell carcinoma

recAP

recombinant human Alkaline Phosphatase

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SGA

small for gestational age

S&P

Standard and Poor s

Teuto

Laborat rio Teuto Brasileiro S.A.

U.K.

United Kingdom

U.S.

United States

VAT

value added tax

VOC

Global Vaccines, Oncology and Consumer Healthcare segment

WRD

Worldwide Research and Development

Zoetis

Zoetis Inc.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 3,

2016

June 28,

2015

July 3,

2016

June 28,

2015

Revenues

13,147

11,853

26,152

22,717

Costs and expenses:

Cost of sales(a)

3,174

2,180

6,026

4,018

Selling, informational and administrative expenses(a)

3,471

3,386

6,856

6,491

Research and development expenses(a)

1,748

1,734

3,478

3,620

Amortization of intangible assets

961

872

1,966

1,811

Restructuring charges and certain acquisition-related costs

316

86

457

146

Other (income)/deductions net

1,068

55

1,398

Income from continuing operations before provision for taxes on income

2,410

3,539

5,971

6,621

Provision for taxes on income

375

905

910

1,610

Income from continuing operations

2,035

2,635

5,060

5,011

Discontinued operations net of tax

Net income before allocation to noncontrolling interests

2,035

2,635

5,061

5,017

Less: Net income attributable to noncontrolling interests

16

25

14

Net income attributable to Pfizer Inc.

2,019

2,626

5,036

5,002

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.33

0.43

0.82

0.81

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.33

0.43

0.82

0.81

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.33

0.42

0.82

0.80

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.33

0.42

0.82

0.80

Weighted-average shares basic

6,068

6,159

6,110

6,181

Weighted-average shares diluted

6,137

6,243

6,176

6,267

Cash dividends paid per common share

0.30

0.28

0.60

0.56

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

July 3,

2016

June 28,

2015

July 3,

2016

June 28,

2015

Net income before allocation to noncontrolling interests

2,035

2,635

5,061

5,017

Foreign currency translation adjustments, net

514

(327

581

(1,635

514

(327

581

(1,635

Unrealized holding gains/(losses) on derivative financial instruments, net

(571

452

(845

137

Reclassification adjustments for realized (gains)/losses(a)

469

(743

130

(510

(102

(291

(714

(373

Unrealized holding gains/(losses) on available-for-sale securities, net

350

(200

479

(527

Reclassification adjustments for realized (gains)/losses(a)

(226

498

(16

745

124

299

463

218

Benefit plans: actuarial gains/(losses), net

(19

(9

(19

22

Reclassification adjustments related to amortization(b)

139

134

278

269

Reclassification adjustments related to settlements, net(b)

22

22

48

62

Other

(57

(29

(18

130

85

118

288

483

Benefit plans: prior service credits and other, net

87

507

87

506

Reclassification adjustments related to amortization(b)

(41

(34

(81

(69

Reclassification adjustments related to curtailments, net(b)

(7

(6

(17

Other

(2

(2

48

464

418

Other comprehensive income/(loss), before tax

669

263

624

(890

Tax provision/(benefit) on other comprehensive income/(loss)(c)

36

228

(5

332

Other comprehensive income/(loss) before allocation to noncontrolling interests

633

35

629

(1,222

Comprehensive income before allocation to noncontrolling interests

2,668

2,670

5,690

3,795

Less: Comprehensive income/(loss) attributable to noncontrolling interests

21

24

(3

Comprehensive income attributable to Pfizer Inc.

2,647

2,663

5,666

3,797

(a)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(b)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(c)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

July 3,

2016

December 31,

2015

(Unaudited)

Assets

Cash and cash equivalents

3,411

3,641

Short-term investments

17,531

19,649

Trade accounts receivable, less allowance for doubtful accounts: 2016 $670; 2015 $384

9,138

8,176

Inventories

7,614

7,513

Current tax assets

3,127

2,662

Other current assets

3,023

2,163

Total current assets

43,845

43,804

Long-term investments

13,124

15,999

Property, plant and equipment, less accumulated depreciation: 2016 $14,637; 2015 $13,502

13,609

13,766

Identifiable intangible assets, less accumulated amortization

43,056

40,356

Goodwill

50,600

48,242

Noncurrent deferred tax assets and other noncurrent tax assets

1,805

1,794

Other noncurrent assets

4,618

3,420

Total assets

170,658

167,381

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

13,724

10,159

Trade accounts payable

3,261

3,620

Dividends payable

1,820

1,852

Income taxes payable

647

418

Accrued compensation and related items

1,594

2,359

Other current liabilities

11,053

10,990

Total current liabilities

32,099

29,399

Long-term debt

30,457

28,740

Pension benefit obligations, net

5,224

6,310

Postretirement benefit obligations, net

1,877

1,809

Noncurrent deferred tax liabilities

28,300

26,877

Other taxes payable

4,116

3,992

Other noncurrent liabilities

5,518

5,257

Total liabilities

107,592

102,384

Commitments and Contingencies

Preferred stock

25

26

Common stock

461

459

Additional paid-in capital

82,138

81,016

Treasury stock

(84,313

(79,252

Retained earnings

73,350

71,993

Accumulated other comprehensive loss

(8,891

(9,522

Total Pfizer Inc. shareholders equity

62,769

64,720

Equity attributable to noncontrolling interests

297

278

Total equity

63,066

64,998

Total liabilities and equity

170,658

167,381

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS OF DOLLARS)

July 3,

2016

June 28,

2015

Operating Activities

Net income before allocation to noncontrolling interests

5,061

5,017

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

2,812

2,461

Asset write-offs and impairments

983

42

Deferred taxes from continuing operations

(10

(183

Share-based compensation expense

387

347

Benefit plan contributions in excess of expense

(857

(842

Other adjustments, net

170

(194

Other changes in assets and liabilities, net of acquisitions and divestitures

(3,316

(1,879

Net cash provided by operating activities

5,230

4,770

Investing Activities

Purchases of property, plant and equipment

(702

(497

Purchases of short-term investments

(8,744

(16,029

Proceeds from redemptions/sales of short-term investments

14,757

20,483

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less

(249

3,020

Purchases of long-term investments

(3,126

(5,422

Proceeds from redemptions/sales of long-term investments

2,427

3,291

Acquisitions of businesses, net of cash acquired

(4,616

(679

Acquisitions of intangible assets

(96

(12

Other investing activities, net

26

333

Net cash (used in)/provided by investing activities

(323

4,487

Financing Activities

Proceeds from short-term borrowings

2,307

2,022

Principal payments on short-term borrowings

(2,291

(11

Net proceeds from short-term borrowings with original maturities of three months or less

2,182

481

Proceeds from issuance of long-term debt

5,031

Principal payments on long-term debt

(4,317

(2,995

Purchases of common stock

(5,000

(6,000

Cash dividends paid

(3,675

(3,483

Proceeds from exercise of stock options

696

981

Other financing activities, net

(2

154

Net cash used in financing activities

(5,069

(8,852

Effect of exchange-rate changes on cash and cash equivalents

(68

(78

Net increase/(decrease) in cash and cash equivalents

(230

327

Cash and cash equivalents, beginning

3,641

3,343

Cash and cash equivalents, end

3,411

3,670

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

1,111

1,124

Interest

903

914

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.

We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 29, 2016 and May 24, 2015. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 3, 2016 and June 28, 2015.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K.

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13.

In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets, Other noncurrent assets, Short-term borrowings, including current portion of long-term debt and Long-term debt, and in the condensed consolidated statement of cash flows for the six months ended June 28, 2015, we performed certain reclassifications to conform to the current presentation of Proceeds from short-term borrowings for debt issuance costs in accordance with the adoption of a new accounting standard (for additional information, see Note 1B).

On June 24, 2016 (the acquisition date), we completed our acquisition of Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ($4.5 billion, net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities and cash flows of Anacor. The operating results for Anacor for five days from June 24, 2016 to July 3, 2016 were immaterial. See Note 2A for additional information.

On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which falls into Pfizer s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan s expenses associated with the terminated transaction (see Note 4). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

On September 3, 2015, we completed our acquisition of Hospira and, commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira. As a result, legacy Hospira operations are reflected in our results of operations, EH s operating results, and cash flows for the second quarter and first six months of 2016, but not for the second quarter and first six months of 2015. Legacy Hospira assets and liabilities are reflected in our balance sheets as of July 3, 2016 and December 31, 2015.

B. Adoption of New Accounting Standards

We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of July 3, 2016, debt issuance costs were $93 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($2 million) and Long-term debt ($91 million). In the December 31, 2015 condensed consolidated balance sheet, we have reclassified debt issuance costs of $79 million ($1 million from Other current assets and $79 million from Other noncurrent assets) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($1 million) and Long-term debt ($79 million) to conform to the current period presentation. For additional information, see Note 7A.

We adopted a new standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our condensed consolidated financial statements in the second quarter and first six months of 2016 from adopting this standard. For additional information, see Note 2A.

We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our condensed consolidated financial statements from adopting this standard.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Note 2. Acquisitions, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment

A. Acquisitions

Anacor Pharmaceuticals, Inc.

On June 24, 2016 (the acquisition date), we completed our acquisition of Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ($4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Included within Anacor s pipeline is crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and provisionally recorded $5.0 billion in Identifiable intangible assets, primarily consisting of $4.8 billion of In-process research and development, and provisionally recorded $1.8 billion of Goodwill and $1.6 billion of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Hospira, Inc.

On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ($15.7 billion, net of cash acquired). Hospira is now a subsidiary of Pfizer. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first six months of 2016 to the provisional amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. Certain estimated values are not yet finalized (see below) and are subject to change. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.

(MILLIONS OF DOLLARS)

Amounts Recognized

as of Acquisition Date (as previously reported as of December 31, 2015)

Measurement Period Adjustments(a)

Amounts Recognized as of Acquisition Date (as adjusted)

Working capital, excluding inventories

274

(16